DAVID GRANOVSKY

Posts Tagged ‘tumor’

ZEROING IN ON LEUKEMIA SMART BOMBS

In PHARMA AND DRUGS, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on January 31, 2017 at 1:30 pm

A little over a week ago, I posted an article that described:
Of the 100 million BULK CANCER CELLS in a 1-cm cancer tumor, there are about 1,000 to 10,000 CANCER STEM CELLS and those cells are up to 15 times more active and may be the only cells responsible for cancer cell reproduction and metastasis.

Scientists have zeroed in even deeper and targeted a new ‘CD99’ molecule expressed on certain stem cells that drive human leukemia malignancies.  They’ve designed antibodies that can directly kill human acute myeloid leukemia (AML) stem cells.

cd99-2164277470_3687e795d0_z

protein-sugar molecule, CD99

Researchers design antibody that recognizes and destroys blood cancer stem cells

Published on January 25, 2017 at 9:44 PM ·

Building on this discovery, the study authors designed an antibody that recognizes and destroys CD99-covered leukemia cells while sparing normal blood stem cells, a finding confirmed by experiments in human cells and in mice with AML cells. Antibodies are immune system proteins that stick to a specific target, like a protein on the surface of invading bacterium. In recent years, researchers have become capable of engineering antibodies so that they target disease-related molecules.

“Our findings not only identify a new molecule expressed on stem cells that drive these human malignancies, but we show that antibodies against this target can directly kill human AML stem cells,” says corresponding study author, Christopher Y. Park, MD, PhD, associate professor in the Department of Pathology at NYU Langone and its Perlmutter Cancer Center.

“While we still have important details to work out, CD99 is likely to be an exploitable therapeutic target for most AML and MDS patients, and we are working urgently to finalize a therapy for human testing,” says Park.

Direct Cell Killing

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) arise from abnormal stem cells that build up in bone marrow until they interfere with normal blood cell production. Patients struggle with anemia, increased risk for infection, and bleeding.

The study results are based on the understanding that cancers, like normal tissues, contain stem cells that give rise to all the other cells. Such “cancer stem cells” are known to be major drivers of many cancer types. In AML, a small group of leukemic stem cells become incapable of maturing into red or white blood cells as intended. Most leukemias respond initially to standard treatment, but relapse is common as standard treatments fail to kill leukemia stem cells, which continue to multiply.

leukemia-741px-symptoms_of_leukemia

The research team became interested in CD99 when they observed that it occurs frequently on AML and MDS cells, and then noted in the literature that CD99 is elevated in a rare bone cancer called Ewing’s Sarcoma. This prompted them to see if CD99 was important in the development of these blood diseases.

When researchers examined stem cell populations from 79 AML and 24 MDS patients, they found that approximately 85 percent of stem cells in both groups expressed high levels of CD99. The levels were so high that diseased stem cells could be cleanly separated from related, normal stem cells in AML patients.

Upon confirming that CD99 was abundant on leukemia stem cells, the research team then made several CD99 antibodies, and chose to focus on the one that most effectively killed those cells. Researchers found that when the study antibody attaches itself to CD99 on the surface of a cancer stem cell, it sends a signal inside the cell that increases the activity of enzymes called SRC-family kinases.

While the team does not yet know why, the binding of their antibody to CD99, and the subsequent activation of these enzymes, causes leukemia stem cells to die. Most cells with genetic mistakes leading to cancer “sense” they are flawed and self-destruct, but CD99, so the theory goes, may be part of a mechanism that prevents this. As the antibody binds to CD99, it appears to undo this block on self-destruction.

“With the appropriate support, we believe we can rapidly determine the best antibodies for use in patients, produce them at the quality needed to verify our results, and apply for permission to begin clinical trials,” says Park.

While the most common acute leukemia affecting adults (22,000 new cases each year) and expected to become more prevalent as the population ages, AML it is still relatively rare, accounting for 1.2 percent of U.S. cancer deaths. About 15,000 mostly elderly patients are diagnosed with MDS each year as well.

 

WITH CANCER, AIM ONLY FOR FURTHER GROWTH

In PHARMA AND DRUGS, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on January 22, 2017 at 10:16 am

Did we just figure out which cells actually cause the creation of more cancer cells?

  • A 1-cm cancer tumor has about 100 million BULK CANCER CELLS.
  • A 1-cm cancer tumor has about 1,000 to 10,000 CANCER STEM CELLS.
  • We know that cancer cells may pass through blood vessel walls to metastasize Moses-stem-cell-pathways-and-maybe-metastatic-cancers/
  • We know that long telomeres increase risk of cancer in cells.

Scientists found that cancer stem cells which have the enzyme called Telomeras, were found to be up to 15 times more active and may be the only cells responsible for cancer cell reproduction and metastasis.
“We can now begin to think of cancer stem cells as being at the heart of tumour regrowth and turn our efforts away from ‘bulk cancer cells’, which don’t really drive tumour recurrence and metastasis.”

Now, we know how to aim at the cells responsible for tumor growth we can change how we fight cancer!

Puts a whole new spin on the Niki Lauda quote:

Stem cell ‘marking’ study offers alterative hypothesis of cancer metastasis

Date:January 18, 2017- Source: University of Salford – Summary: Stem cells are among the most energetically activated, migratory and proliferative sub-populations of tumour cells, according to observations by scholars at the Biomedical Research Centre at the University of Salford.

Cancerous stem cells are often left behind after chemotherapy with the potential to create new tumours — a process called recurrence and metastasis.

In research published in the journal Oncotarget, the Salford team conclude that stem cell characteristics and behaviour are instrumental in metastasis and believe the key to their reactivation is an enzyme called Telomerase, or hTERT.

Using lung, breast and ovarian cancer cells, the team set out to identify which cells are cancerous by their levels of Telomerase, an enzyme which endows cells with the ability to multiply.

To achieve this, they followed Telomerase activity with a fluorescent protein, GFP, more commonly found in jellyfish, effectively colouring each cells to mark it either ‘active’ or ‘inactive’.

Cells highlighted ‘fluorescent’ (hTERT-high) were found to be up to 15 times more active than others with an vastly increased capacity for migration and cell proliferation.

Michael Lisanti, Professor of Translational Medicine at the University of Salford said: “We reasoned that if we could spot the telomerase activity, we could identify which cells were cancerous.

“What we had not expected was to find the very rapid rate of proliferation of the cancer stem cells.

“Clearly, this contradicts the accepted view that stem cells do not proliferate quickly, and offers an alternative view of the process of metastasis, and moreover, a method of identifying, isolating and potentially killing tumour-forming cells.”

As part of the study, the team found that FDA-approved drugs, such as doxycycline and palbociclib, were effective at halting cancer stem cell propagation. Palbociclib blocks the activity of proteins known as cyclin-dependent kinases (CDK) and inhibits the division of cancer cells, but until now hadn’t been shown to effectively block cancer stem cell reproduction.

“The use of these FDA-approved drugs may provide a mechanism for treating metastatic disease on a larger scale and certainly opens the way for new Phase II clinical trials in multiple cancer types,” adds Professor Lisanti.

Dr Federica Sotgia, Reader of Translational Medicine at the University of Salford said: “We can now begin to think of cancer stem cells as being at the heart of tumour regrowth and turn our efforts away from ‘bulk cancer cells’, which don’t really drive tumour recurrence and metastasis.”


Story Source:

Materials provided by University of Salford. Note: Content may be edited for style and length.


Journal Reference:

  1. Gloria Bonuccelli, Maria Peiris-Pages, Bela Ozsvari, Ubaldo E. Martinez-Outschoorn, Federica Sotgia, Michael P. Lisanti. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity. Oncotarget, 2016; DOI: 10.18632/oncotarget.14196

DO ADULT STEM CELLS CAUSE CANCER?

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES on July 1, 2014 at 4:31 pm

NO!

cancer-free-zone

What do you get when you add 1,100 ADULT STEM CELL PATIENTS studied over 5 years,

plus another 1,873 ADULT STEM CELL PATIENTS studied over an average 12.5 years,

plus another ~7,000 ADULT STEM CELL PATIENTS in studies and FDA clinical trials data?

~10,000 ADULT STEM CELL TREATMENT PATIENTS showing NO CANCER!

 

“A total of 1873 patients were treated from 1990 to 2006 with bone marrow-derived concentrated cells. Patients were monitored for cancer incidence from the date of the first operation (1990) until death, or until December 31, 2011. The mean follow-up time was 12.5 years (range, five to twenty-two years)…No tumor formation was found at the treatment sites on the 7306 magnetic resonance images and 52,430 radiographs among the 1873 patients…This study found no increased cancer risk in patients after application of autologous cell-based therapy using bone marrow-derived stromal progenitor cells either at the treatment site or elsewhere in the patients after an average follow-up period of 12.5 years.

The upshot? This most recent study, as well as others, FDA clinical trials data, and the data we have published now amounts to about 10,000 patients who have been treated with adult stem cells and extensively tracked for this issue. There is no evidence that adult stem cells cause cancer. There is no rational reason for the fear, other than a completely different type of cell (ESC) that happens to have a similar name (stem cell) can cause teratomas – hence the confusion!”

Tumors, cancers and teratomas may result from Embryonic stem cell (ESC) treatments or Induced Pluripotent stem cell (iPSC) treatments

but NOT FROM ADULT STEM CELL TREATMENTS.

Sources:

PANCREATIC CANCER TUMORS DEFEATED WITH CORD BLOOD STEM CELLS

In ALL ARTICLES, SCIENCE & STEM CELLS, VICTORIES & SUCCESS STORIES on June 25, 2014 at 11:42 am

fight pancreatic cancer FPC_shirt


PANCREATIC CANCER TUMORS DEFEATED WITH CORD BLOOD STEM CELLS

What happens when you “genetically engineer MSCs isolated from human umbilical cord blood so that they expressed IL-15” (which fights cancer tumors) and inject them into mice with pancreatic  tumors?

  • The IL-15 migrate to the tumor
  • Other cancer and tumor fighting immune cells migrate to the tumor
  • The IL-15 attack the tumor
  • Other cancer and tumor fighting immune cells attack the tumor
  • Tumors show cell death
  • Tumor growth is significantly inhibited
  • Survival is prolonged
  • The mice immune systems are effectively vaccinated against future tumor growth

Scientists “used these souped-up cells to treat In mice afflicted with pancreatic tumors. Pancreatic cancer is an indiscriminate killer, since by the time it causes any symptoms, it is usually so advanced, that there is little to be done in order to treat it. Thus new strategies to treat this type of cancer are eagerly being sought. Systemic administration of IL-15-expressing MSCs significantly inhibited tumor growth and prolonged the survival of tumor-bearing mice. The tumors of these mice showed extensive cell death, and other types of immune cells known to fight tumor cells (NK and T cells) had also accumulated around the tumor. Other experiments confirmed that the injected MSCs did indeed migrate toward the tumors and secrete IL-15 at the site of the tumors…Interestingly, those mice that were cured from the pancreatic tumors, appeared to have a kind of resistance of these tumors. Namely, when Fan and his colleagues tried to reintroduce the same tumor cells back into the cured mice, the tumor cells would not grow. Thus the engineered MSCs not only tuned the immune system against the tumor, but they effectively vaccinated the mice against it as well.”

via http://beyondthedish.wordpress.com/2014/06/23/engineered-stem-cels-from-human-umbilical-cord-blood-eradicates-pancreatic-tumor/

 

 

Thanks Squeeky!

mouse-grown-from-stem-cells

Stem cells VS chemo resistant metastatic esophageal cancer?

In ALL ARTICLES, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES on January 28, 2013 at 9:00 am

Picture_16

“…chemo resistant metastatic esophageal cancer…”

I was recently contacted by a patient with chemo resistant metastatic esophageal cancer.  This is the 2nd patient in a row with this condition.  The prior one presented with stage 4 esophageal cancer. We had to determine if the cancer is/is not in the bone marrow to assess how much it has metastasized or whether it is localized to the esophagus. In any case, the first patient was treated with the protocol I posted previously and it reduced the cancer cell markers by 40% within 3 weeks. The mesenchymal stem cells recruited NTK (Natural Killer Cells) which reduce the tumors and cancer cell markers. The patient is now 3 months post op (as of 1/26/13) and is doing extremely well. He is at Stage 1 down from Stage 4. He has decided to receive a second treatment and we are hopeful he will retain full remission.
– DG

Stem cells for cancer? Yes.

This works because:
“…tumor-oriented homing capacity of mesenchymal stem cells (MSCs), the application of specific anticancer gene-engineered MSCs has held great potential for cancer therapies. The dual-targeted strategy is based on MSCs’ capacity of tumor-directed migration and incorporation and in situ expression of tumor-specific anticancer genes.”
From http://www.wjgnet.com/1948-0210/pdf/v3/i11/96.pdf

Look for this article and others on my blog: repairstemcell.wordpress.com

STEM CELL VACCINE IN DEVELOPMENT TO FIGHT CANCER

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on January 10, 2013 at 9:00 am

A1455614-07B7-A460-2C9B7A124BB3A86F_1

Cancer Stem Cell Vaccine in Development Shows Anti-tumor Effect

Philadelphia – Scientists may have discovered a new paradigm for immunotherapy against cancer by priming antibodies and T cells with cancer stem cells, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.”

“This is a major breakthrough in immunotherapy research because we were able to use purified cancer stem cells to generate a vaccine, which strengthened the potency of antibodies and T cells that selectively targeted cancer stem cells.  We found that these enriched cancer stem cells were immunogenic and far more effective as an antigen source compared with the unselected tumor cells normally used in previous immunotherapy trials. The mechanistic investigations found that when antibodies were primed with cancer stem cells, they were capable of targeting cancer stem cells and conferring anti-tumor immunity.”

–          Qiao Li, Ph.D., a research assistant professor, department of surgery, University of Michigan.

imgname--threeparent_embryo---50226711--images--IVF_egg

The researchers also found that cytotoxic T lymphocytes harvested from cancer stem cell-vaccinated hosts were capable of killing cancer stem cells in vitro.”

http://www.aacr.org/home/public–media/aacr-press-releases.aspx?d=2744

Journal Reference:  Cancer Stem Cell Vaccination Confers Significant Antitumor Immunity. Cancer Research, 2012; 72 (7): 1853 DOI: 10.1158/0008-5472.CAN-11-1400

STEM CELL THERAPIES TARGET OVARIAN CANCER

In STEM CELLS IN THE NEWS on January 9, 2013 at 10:46 pm

Picture-32

“Each year, about 20,000 women in the United States get ovarian cancer. Among women in the United States, ovarian cancer is the eighth most common cancer and the fifth leading cause of cancer death, after lung and bronchus, breast, colorectal, and pancreatic cancers. Ovarian cancer causes more deaths than any other cancer of the female reproductive system, but it accounts for only about 3% of all cancers in women. When ovarian cancer is found in its early stages, treatment is most effective.†”

Ovarian cancer stem cell study puts targeted therapies within reach

“Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer’s growth and patient prognosis.  Yingqun Huang, M.D. and her colleagues have demonstrated a connection between two concepts that are revolutionizing the way cancer is treated.

First, the “cancer stem cell” idea suggests that at the heart of every tumor there is a small subset of difficult-to-identify tumor cells that fuel the growth of the bulk of the tumor. This concept predicts that ordinary therapies typically kill the bulk of tumor cells while leaving a rich environment for continued growth of the stem cell tumor population.  The second concept defines a critical role for the tumor cells’ “microenvironment,” which is the special environment required for cancer cell growth and spread.  “Both concepts have particular relevance for the treatment of adult solid tumors such as ovarian cancer, which has been notoriously difficult to diagnose and treat. Ovarian cancer patients are plagued by recurrences of tumor cells that are resistant to chemotherapy, ultimately leading to uncontrolled cancer growth and death.”

Cell Cycle Vol. 12, Issue 1

Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2009 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2013. Available at: http://www.cdc.gov/uscs.

Need information on a specific disease, click HERE for more information.

EMBRYONICS’ BLEAK FUTURE AND BOTCHED PAST

In ALL ARTICLES on November 15, 2011 at 6:42 pm

Request more treatment info.

EMBRYONICS’ BLEAK FUTURE AND BOTCHED PAST

BLEAK FUTURE

I just received a comment from MB and despite Geron and the rest of the world abandoning embryonic stem cells for adult, he is still optimistic about the future of embryonic stem cells (with a little plug snuck in for a company he probably owns stock in).

My original comment:

embryonic research has been 100% fruitless (in regard to generating
treatments) for well-funded and government supported scientists around the world for the last 13 years.  Embryonic stem cells are the only significant obstacles to embryonic stem cell treatments.  Adult stem cells on the other hand have successfully treated 10s of thousands over the past decade.

MB’s response:

hESCs (human embryonic stem cells) have only been around for 13 years compared to adult stem cells 30+ years…. give it some time… human embryonic stem cells (especially ACT’s embryo SAFE blastomere-derived) will be THE GOLD standard 🙂  watch and SEEE the difference…soon..

My response:

MB – Not even close.   Embryonic stem cells have been around for way longer than since James Thompson and friends derived the first human embryonic stem cell line at the University of Wisconsin-Madison in 1998.

To clarify:

“Research in the human stem cell field grew out of findings by Canadian scientists Ernest A. McCulloch and James E. Till in the 1960s.”

1963: Becker AJ, McCulloch EA, Till JE (1963). “Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells”. Nature 197: 452-4. PMID 13970094.

1963: Siminovitch L, McCulloch EA, Till JE (1963). “The distribution of colony-forming cells among spleen colonies”. Journal of Cellular and Comparative Physiology 62: 327-36. PMID 14086156.

1978: Stem cells were discovered in human cord blood

1981: First in vitro stem cell line developed from mice

1981 – Mouse embryonic stem cells are derived from the inner cell mass

That’s 30 years ago!

Evans, M.J. & Kaufman, M. Establishment in culture of pluripotential stem cells from mouse embryos. Nature 292, 151–156 (1981).

1981 – Martin, G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci USA 78, 7634–7638 (1981).

1984 – Andrews, P.W. et al. Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Lab. Invest. 50, 147–162 (1984).

Blastomeres isolated from the ICM of mammalian embryos and grown in culture are known as embryonic stem (ES) cells. These pluripotent cells, when grown in a carefully coordinated media, can give rise to all three germ layers (ectoderm, endoderm, and mesoderm) of the adult body.

1986: Robertson, Elizabeth , et al. Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector. Nature 323, 445 – 448 (02 October 1986)

1988: Embryonic stem cell lines created from a hamster

1995: First embryonic stem cell line derived from a primate

1995: Thomson, J.A. et al. Isolation of a primate embryonic stem cell line. Proc. Natl. Acad. Sci. USA 92, 7844–7844 (1995).

And then we get to what MB considers the “discovery of embryonic stem cells”:

1998 – James Thomson and coworkers derive the first human embryonic stem cell line at the University of Wisconsin-Madison.

Not to worry, though MB.  Adult stem cells HAVE been used in bone marrow transplants for over 40 years so they still have the upper hand in “time we’ve worked with them.”  Then again, it was only in 1998 that adult stem cells were considered for treating other illnesses.

Just out of curiosity, besides

“embryonic stem cells have proven 100% fruitless (in regard to generating treatments) for well-funded and government supported scientists around the world for the last 13 years,”

how do you plan on addressing these other embryonic stem cell issues to name a few?

  1. they create cysts and tumors that can develop into cancer at the site of the injection and injury
  2. rejection issues require immunosuppressive drugs for the ill patient
  3. embryonic stem cells (and induced pluripotent stem cells) carry the genetic anomalies of the donor
  4. they have to date treated zero diseases successfully
  5. scientists probably need to cure cancer first to use them
MIRROR THE RESULTS

MIRROR THE RESULTS

But if MB can mirror the results of  the success rate of adult stem cell treatments (~65% of patients have significant improvement in their incurable, chronic or terminal illnesses) and do so without the side effects alluded to above (adult stem cells have virtually zero side effects except for sometimes additionally fixing more than the intended organ/illness) then I would love to hear about it!

A HISTORY OF THE GERON EMBRYONIC STEM CELL FIASCO

In BUSINESS OF STEM CELLS on November 15, 2011 at 1:27 am

https://i0.wp.com/geekcentricity.com/wp-content/uploads/2010/09/Fiasco.jpg

Embryonic stem cell treatment are now an unrealized potential.

Adult stem cell treatments are a realized potential.

To see if your condition can be treated with Adult stem cells, please fill out this form: http://bit.ly/PATIENTQUESTIONNAIRE

GERON GIVES UP on EMBRYONIC STEM CELLS!

In STEM CELLS IN THE NEWS on November 14, 2011 at 11:13 pm

THE

WAR

IS

OVER!!

GERON THROWS IN THE TOWEL!If stem cell treatments were a boxing match, Embryonic stem cell treatments would be the 500 lb Gorilla and Adult stem cell treatments would be the small, unknown underdog.   Today, that Gorilla threw in the towel!

Despite the huge disparity in their media coverage, with positive Embryonic stem cell potential articles outnumbering all Adult stem cell articles by 1,000 to one, only Adult stem cells have a proven history of safety and efficacy, only Adult stem cell treatments are available today.  Click here to see if your condition can be treated with Adult stem cells:

While Geron and the US media, big Pharma, the AMA and the FDA have all given Embryonic stem cell their full throated support, the number of patients helped with adult stem cells is in the 10s of thousands while the number of patients helped by Embryonic stem cells in zero.

HORSE FALLING DOWN DURING RACEIf Embryonic treatments were a horse race, Geron would be the strongest horse in the field.  Geron would be the horse who was 9/10 of the way around the track with all other competitors still milling about in the starting blocks.  So what would make that horse stop dead in his tracks, fall flat on his face and walk away from the race?

What does it mean for the other Embryonic focused companies when the front runner pulls out of the race?

What would cause the leading Embryonic stem cell Pharmaceutical company with multiple Embryonic stem cell products in development to end all of their Embryonic stem cell programs? 

Product Product Description Application Development Stage
GRNOPC1 Oligodendrocyte Progenitor Cells Spinal Cord Injury Phase I Clinical Trial
GRNCM1 Cardiomyocytes Heart Disease Preclinical
GRNIC1 Islets Type 1 Diabetes Research
GRNCHND1 Chondrocytes Osteoarthritis Research
Hepatocytes ADME Drug Screening Research
GRNVAC2 Mature Dendritic Cells Cancer Immunotherapy Product Research
Immature Dendritic Cells Immune Rejection Research
Osteoblasts Osteoporosis Research

via Geron.com

Perhaps their clinical trial patients developed cysts and tumors as do all Embryonic stem cell patients.  Perhaps Geron decided to end their trials before these tumors and cysts turned into cancer so they could still say their product “has been well tolerated with no serious adverse events.”

Perhaps Geron couldn’t figure out how to address the need for immunosuppressive drugs required to implant a human with ALL Embryonic stem cells when there are many Adult stem cells that have no rejection issues.

Perhaps Geron couldn’t determine how to deal with Embryonic stem cells carrying the genetic abnormalities and maladies of the donor.

Or perhaps they read some of the quotes from my articles going back to March of 2009:

  • To date, ESC research has been 100% fruitless (in regard to generating treatments) for well-funded + government supported scientists around the world for the last 11 years.
  • Dr James Thomson, father of ESC research said: “…[ESC] are not being used in any clinical applications yet, while alternatives such as adult stem cells figure in scores of therapies.”
  • Ian Wilmut, who led the team that cloned Dolly the sheep, abandoned his license to attempt human cloning, saying that the researchers “may have achieved what no politician could: an end to the [ESC] debate.”
  • Dr. Bernadine Healy, former director of the NIH in U.S. News & World Report: “…[ESC], once thought to hold the cure for Alzheimer’s, Parkinson’s, and diabetes, are obsolete….. In fact, adult stem cells, which occur in small quantities in organs throughout the body for natural growth and repair, have become stars despite great skepticism early on.
Or maybe they reviewed the timeline for Embryonic stem cell success and realized they couldn’t afford 50 YEARS OF RESEARCH!
Dr. Colin McGuckin, a noted UK embryonic research leader at Newcastle U. before departing for more useful RSC research in France announced:

  • “For me, the unnecessary row over stem cells has obscured the very real issue that patients are waiting to be treated…The best estimates of the embryonic scientists in our own university in Newcastle is that embryonic stem cells may not be able to help people this side of 50 years. That’s my lifetime. And that’s worrying. We can’t wait that long.”
I do have to applaud their spin department.  It is a brilliant move to take the news story
“GERON GIVES UP ON EMBRYONIC STEM CELLS”
and spin it into
“GERON PUTS 100% FOCUS INTO CURING CANCER.” 
Even so, we are not fooled.  The red headed step child in the family always knows when they are neglected. 
They also published their press release at 4:05 Eastern so the regular stock market was closed and couldn’t react to the news. Unfortunately for them, their stock dropped over 20% in after hours trading.
Whatever the reason for Geron abandoning Embryonic stem cells, we can now finally exalt that THE WAR IS OVER and get on with Adult Stem Cell Treatments, the only stem cells to cure a human patient.

ADULT STEM CELL = ASC

  • SOURCE/DERIVED FROM•comes from blood, umbilical cords, bone marrow, placenta fat tissue, muscle, nasal neurological, breast milk, menstruation, dental pulp, and many more
  • PURPOSE IN BODY•they are the body’s natural healing cells
  • OBSTACLES+SIDE EFFECTS•~zero problems (virtually zero side effects)
  • TREATMENT HISTORY•used in bone marrow transplants to treat cancer for 40 years
  • TREATMENT HISTORY•can currently treat 130+ diseases safely and effectively (CP, MS, Autism, Diabetes, CHF, PAD, etc)
  • To see if your condition can be treated with Adult stem cells, please fill out this form: http://bit.ly/PATIENTQUESTIONNAIRE

via STEM CELLS 101

  • 100+ DISEASES treated around the world with adult stem cells!
  • 60-70% SUCCESS RATE typical therapeutic benefit on INCURABLE DISEASES!!
  • POTENTIAL CURES of Autism, Parkinson’s, AIDs, Diabetes, Heart Disease and more!
  • HUGE REWARDS of life extension!
  • SIGNIFICANTLY IMPROVED quality of life!

https://i2.wp.com/www.maniacworld.com/muhammad-ali-2.jpg

Geron to Focus on Its Novel Cancer Programs
Company Plans to Partner All Stem Cell Programs

MENLO PARK, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN) today announced that, effective immediately, the Company will focus on its first-in-class oncology programs. As a consequence, the Company will discontinue further development of its stem cell programs and is seeking partners for these novel assets.

“Our employees, collaborators and shareholders can be proud of the pioneering role they have played to advance our stem cell technology into the clinic”

“In the current environment of capital scarcity and uncertain economic conditions, we intend to focus our resources on advancing our Phase 2 clinical trials of imetelstat and GRN1005. These two novel and promising oncology drug candidates target major unmet medical needs and have important clinical development milestones occurring over the next 20 months,” said Geron’s Chief Executive Officer, John A. Scarlett, M.D. “By narrowing our focus to the oncology therapeutic area, we anticipate having sufficient financial resources to reach these important near-term value inflection points for shareholders without the necessity of raising additional capital. This would not be possible if we continue to fund the stem cell programs at the current levels.

…The decision to narrow Geron’s technology and therapeutic focus was made after a strategic review of the costs, value inflection timelines and clinical, manufacturing and regulatory complexities associated with the Company’s research and clinical-stage assets. With this decision, Geron is eliminating 66 full-time positions, representing 38% of its workforce. As a result, the Company expects one-time cash expenditures of approximately $5 million in the fourth quarter of 2011 and approximately $3 million in the first half of 2012. Geron expects to end 2011 with cash and investments in excess of $150 million.

Geron is seeking partners with the technical and financial resources to enable further development of its stem cell programs. “Our employees, collaborators and shareholders can be proud of the pioneering role they have played to advance our stem cell technology into the clinic,” said Dr. Scarlett. “Stem cells continue to hold great medical promise. We believe that our leadership role in the field and the quality of our stem cell assets — which are widely recognized as being among the most innovative, comprehensive and advanced cell therapy programs in the world — will be an important point of differentiation in our discussions to partner these assets.” In order to facilitate transfer of these programs to partners, Geron will retain a core group of employees from its stem cell operations through the end of the second quarter of 2012.

Geron plans to close the GRNOPC1 trial for spinal cord injury to further enrollment, although it will continue to follow all enrolled patients, accruing data and updating FDA and the medical community on their progress. In this trial, GRNOPC1 has been well tolerated with no serious adverse events

Read more

Related articles:

A HISTORY OF THE GERON EMBRYONIC STEM CELL FIASCO November 15, 2011

EMBRYONICS’ BLEAK FUTURE AND BOTCHED PAST November 15, 2011

To see if your condition can be treated with Adult stem cells, please fill out this form:

%d bloggers like this: